Introduction
============

COPD and cardiovascular disease are distinctly related. Electrocardiographic (ECG) abnormalities such as bundle branch blocks, axis deviations, and arrhythmias are common in patients with COPD.[@b1-copd-13-2157] Such patients also have a higher cardiovascular morbidity and mortality rate than the general population.[@b2-copd-13-2157] In addition, half of the deaths of patients with COPD are attributable to cardiovascular disease.[@b2-copd-13-2157] Previous studies suggested that patients with COPD have a 2- to 3-fold increased risk of sudden cardiac death (SCD).[@b3-copd-13-2157] However, underlying mechanisms of the association between COPD and SCD are currently unclear and predictors of malignant cardiac arrhythmias that lead to SCD in COPD have not yet been defined.[@b4-copd-13-2157] Lahousse et al[@b5-copd-13-2157] presented the first data showing COPD as an independent risk factor for SCD.

According to recent studies, the interval between the peak and end of the T wave (Tp--Te) on ECG may stand for the index of total (transmural, apicobasal, and global) dispersion of repolarization.[@b6-copd-13-2157],[@b7-copd-13-2157] Furthermore, an increased Tp--Te interval could be a practical index to estimate cardiovascular mortality and ventricular tachyarrhythmias.[@b8-copd-13-2157],[@b9-copd-13-2157]

COPD is associated with some ECG changes including prolonged QT interval, as described previously.[@b10-copd-13-2157],[@b11-copd-13-2157] The Tp--Te interval is a new marker for ventricular arrhythmias and repolarization heterogeneity.[@b12-copd-13-2157]--[@b15-copd-13-2157]

To date, no algorithm has been defined for the arrhythmic risk stratification of patients with COPD. Therefore, our aim was to define a new ECG parameter for ventricular arrhythmias and SCD in patients with COPD.

Methods
=======

Study population
----------------

We enrolled 134 patients who were admitted to our outpatient clinic. Patients already known as having COPD according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria who were under follow-up for their disease were included.[@b16-copd-13-2157] Forty healthy age- and sex-matched subjects were enrolled as a control group. Patients were classified using COPD assessment test scores, breathlessness level using the modified Medical Research Council dyspnea scale, and exacerbations history as recommended by GOLD.[@b16-copd-13-2157]

Inclusion criteria included the following: patients were stable, diagnosed previously, and under follow-up for COPD.

The exclusion criteria of the present study were as follows: pregnancy; sepsis; neoplasms; current hemodialysis; acute coronary syndromes; severe electrolyte imbalances; acute cerebrovascular disease; aortic dissections; decompensated heart failure; surgery within the past 30 days; prior pulmonary embolism or deep venous thrombosis; acute or chronic infectious diseases; acute or chronic inflammatory diseases such as rheumatoid arthritis, systemic lupus erythematosus, or vasculitis; and patients with prior myocardial infarction or heart failure with low ejection fraction (\<50%).

The demographic, clinical, and laboratory characteristics of the study groups were taken from the patients' histories and results of physical examinations, which were collected by chest disease physicians at admission.

ECG measurements
----------------

A 12-lead ECG was recorded on paper at 25 mm/s and 10 mm/mV gain at rest in the supine position. All ECGs were scanned and analyzed. All QT intervals were measured by 2 different cardiologists. Interobserver correlation for determining Tp--Te interval was assessed using the κ test, and there was a strong correlation between the observers (κ: 0.864, *p*\<0.001). The Tp--Te interval was identified as the interval from the peak of the T wave to the end of the T wave. Tp--Te intervals were taken from precordial leads.[@b8-copd-13-2157] An average value of 3 readings was analyzed for each lead.

Ethical approval
----------------

The Local Ethics Committee of Istanbul University, Turkey, approved the study protocol. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Written informed consent was obtained from all individual participants included in the study.

Statistical analysis
--------------------

Kolmogorov--Smirnov test was used for testing normal distribution. Mann--Whitney *U*-test and the independent sample *t*-test were used for quantitative variables. *χ*^2^ test was used for the analysis of qualitative data, and Fischer's test was used when *χ*^2^ test conditions were not formed. Statistical analyses were made using SPSS 22.0 (IBM Corporation, Armonk, NY, USA).

Results
=======

The patients' and control groups' baseline demographic parameters, COPD stages, and dyspnea scores are shown in [Tables 1](#t1-copd-13-2157){ref-type="table"} and [2](#t2-copd-13-2157){ref-type="table"}. There was no significant difference between the controls and study group for age or sex (*p*=0.207, *p*=0.267, respectively). The cigarette smoking was estimated to be 44.29±2.7 pack-years. All of our patients had persistent airflow limitation, which was shown using spirometry. Patients' forced expiratory volume in 1 second/forced vital capacity ratio was 52.78%±15.99%. Thirteen (9.7%) of our patients used biomass and coal as their main source of energy for cooking. Forty-five (33.6%) patients were still smoking cigarettes; however, 78 (58.2%) quit smoking. Twenty-one (15.7%) patients had been hospitalized because of COPD exacerbation in the previous year, and 88 (65.7%) visited outpatient clinics. Hypertension was the most frequent comorbidity among the study population.

The Tp--Te measured from chest leads V1--6 of COPD and control group are compared in [Table 3](#t3-copd-13-2157){ref-type="table"}. There were significant differences in all leads ([Table 3](#t3-copd-13-2157){ref-type="table"}). Receiver operating characteristic curve analyses showed that the most sensitive and specific area under the curve was for lead V4 with a value of 0.83 ([Table 4](#t4-copd-13-2157){ref-type="table"}).

For Tp--Te \>80, the sensitivity was 78.1% and the specificity was 80%. The receiver operating characteristic curve for Tp--Te V4 is shown in [Figure 1](#f1-copd-13-2157){ref-type="fig"}.

All patients with COPD were divided into 4 groups according to the recommendation by GOLD. When examining the COPD groups according to lead V4, there was only a statistically significant increase in patients who were Stage D ([Table 5](#t5-copd-13-2157){ref-type="table"}). There were no significant differences between patients who were Stage A, B, or C ([Table 5](#t5-copd-13-2157){ref-type="table"}; [Figure 2](#f2-copd-13-2157){ref-type="fig"}). Patients were grouped in the light of revised GOLD 2017, and there was no relation between Tp--Te intervals and FEV values.

Discussion
==========

Cardiovascular morbidity and mortality in the population of patients with COPD is higher than in the overall population. For this reason, we need to develop new methods to predict patients who are at risk of SCD. The relationship between COPD and malignant ventricular arrhythmias causing SCD is still unknown. Surface ECG is an easy and cost-effective method to predict SCD. A new parameter, the Tp--Te, which shows the risk of malignant ventricular arrhythmias and SCD, has not previously been studied in patients with COPD. Our study is the first to prove a prolonged Tp--Te interval in patients with COPD.

Lahousse et al[@b5-copd-13-2157] presented the first study showing COPD as an independent risk factor for SCD. They showed a 2-fold increased risk of SCD in patients with COPD. The study demonstrated that patients with COPD died of SCD more frequently at night, logically due to decreased ventilation and increased hypercapnia, which may cause more nocturnal ventricular arrhythmias.[@b5-copd-13-2157] In addition, Lahousse et al[@b5-copd-13-2157] found that SCD was higher in patients with frequent exacerbations of COPD than in patients with stable outcomes of COPD. In our study, significantly increased Tp--Te values observed in group D patients for lead V4 supports this situation. Hawkins et al[@b17-copd-13-2157] proved that COPD was an independent predictor of death in patients with acute myocardial infarction. COPD can increase both cardiovascular and noncardiovascular events such as pulmonary disease, malignancy, and infection.

Several underlying mechanisms cause the increased risk of SCD in patients with COPD. One of these mechanism is β-adrenergic agonists, which are generally used in the treatment of COPD and can decrease the ventricular refractory period and increase the risk of ventricular arrhythmias.[@b18-copd-13-2157],[@b19-copd-13-2157]

In addition, sympathetic overactivity and increased oxidative stress, which also exist in the COPD population, have been proven to participate in ventricular arrhythmias and SCD. Increased sympathetic activity has been linked with cardiac electrical instability, and therefore the progression to ventricular arrhythmia.

Previous studies have demonstrated the prolongation of the QTc interval in patients with hypoxemic COPD.[@b20-copd-13-2157] QTc interval \>450 ms is an independent risk for ventricular arrhythmias.[@b4-copd-13-2157]

Smoking is also another well-known underlying arrhythmogenic factor in patients with COPD. It is worth noting that nicotine can activate the release of catecholaminergic chemokines, thus increasing blood pressure and heart rate, and may decrease the threshold for ventricular arrhythmias.[@b21-copd-13-2157] Oxidative stress and carbon monoxide, as other components of cigarette smoke, probably play a vital role in triggering ventricular arrhythmias.[@b21-copd-13-2157]

Previous clinical trials have demonstrated that prophylactic use of implantable cardioverter--defibrillator (ICD) can reduce SCD in patients with poor left ventricular ejection function (≤35%). This survival benefit has been shown in patients with COPD who have low left ventricular ejection fraction.[@b22-copd-13-2157] Bilchick et al[@b23-copd-13-2157] showed that COPD was an independent risk factor for mortality (hazard ratio: 1.70; 95% confidence interval: 1.61--1.80) in a study with primary prevention ICD implantation. However, COPD diagnosis alone is not sufficient for ICD implantation. Some additional criteria that can also be used include a cutoff Tp--Te interval, especially in lead V4 or QTc interval, for predicting COPD patients in whom ICD implantation can be performed.

The current study has some limitations. We performed standard surface 12-lead ECG; it is better to use 24-h ECG monitoring to predict Tp--Te interval change in a study group. In addition, the current study had a cross-sectional study design, and it would be better if it were a prospective study design to establish a relationship between prolonged Tp--Te interval in patients with COPD, malignant ventricular arrhythmias, and SCD. Controlled studies involving large patient groups are needed to establish whether a prolonged Tp--Te interval promotes malignant ventricular arrhythmia and SCD in patients with COPD.

Conclusion
==========

COPD has emerged as an important risk factor for ventricular arrhythmias and SCD. To date, no algorithm has been defined for arrhythmic risk stratification of patients with COPD to protect patients from SCD. So, our aim was to define a new ECG parameter which is connected with ventricular arrhythmias and SCD in patients with COPD. Tp--Te interval is a new and useful parameter which can be assessed using surface ECG easily. We demonstrated strong evidence that Tp--Te intervals were increased in patients with COPD, which suggests that there may be an association among COPD, ventricular arrhythmias, and SCD. Nonetheless, further prospective studies should be done.
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![ROC curve for Tp--Te V4.\
**Abbreviations:** ROC, receiver operating characteristic; Tp--Te, interval between the peak and end of the T wave.](copd-13-2157Fig1){#f1-copd-13-2157}

![Tp--Te V4 measurements in COPD patients according to stages.\
**Abbreviation:** Tp--Te, interval between the peak and end of the T wave.](copd-13-2157Fig2){#f2-copd-13-2157}

###### 

Baseline demographic and respiratory test findings in the control and COPD groups

  Findings                      Control group   Case group    *p*-value                  
  ----------------------------- --------------- ------------- ------------ ------------- ---------------------------------------------------
  Age, years                    58.2±6.7        58 (44--65)   60.2±9.4     61 (34--82)   0.207[a](#tfn1-copd-13-2157){ref-type="table-fn"}
  Sex                                                                                    
   Female                       10 (24.39)                    23 (17.16)                 0.267[b](#tfn2-copd-13-2157){ref-type="table-fn"}
   Male                         30 (73.2)                     111 (82.8)                 
  mMRC dyspnea score                                                                     
   Stage 0                                                    11 (8.2)                   
   Stage I                                                    59 (44.0)                  
   Stage II                                                   26 (19.4)                  
   Stage III                                                  14 (10.4)                  
   Stage IV                                                   24 (17.9)                  
  Combined assessment of COPD                                                            
   Stage A                                                    46 (34.3)                  
   Stage B                                                    23 (17.2)                  
   Stage C                                                    26 (19.4)                  
   Stage D                                                    39 (29.1)                  

**Note:**

Student's *t*-test,

*χ*^2^ test.

**Abbreviations:** mMRC, modified Medical Research Council; SD, standard deviation.

###### 

Baseline demographic and biochemical findings in study population

  Findings              n     Minimum   Maximum   Mean     SD
  --------------------- ----- --------- --------- -------- --------
  Age, years            134   34        82        60.2     9.42
  Smoking               133   0         156       44.29    31.46
  Saturation, %         134   75        99        96.60    2.97
  CAT score             133   1         40        14.01    8.42
  WBC, 10^3^/µL         130   4.83      14.9      82.13    204.16
  RBC, 10^6^/µL         130   3.81      6.76      48.68    0.51
  HB, g/dL              130   9.7       17.6      14.55    14.35
  HCT, %                130   29.9      53.5      43.51    42.8
  Sedimentation, mm/h   120   1         80        18.39    15.27
  Glucose, mg/dL        95    50        260       100.24   28.04
  Urea, mg/dL           118   16        66        33.41    9.05
  Creatinine, mg/dL     118   0.57      1.25      0.87     0.16
  Uric acid, mg/dL      85    2.4       8.9       5.18     11.15
  Total protein, g/dL   92    5.6       8.6       7.45     0.47
  Albumin, g/dL         94    3.2       5.2       4.32     0.34
  Ca, mg/dL             93    8.4       10.5      9.45     0.46
  Na, mEq/L             91    130       145       139.74   2.58
  K, mmol/L             92    3.5       5.3       4.51     0.33
  CRP, mg/L             130   0         67        5.95     7.63
  FEV~1~ LT             134   0.44      3.14      15.21    0.59
  FEV~1~ %              134   12.3      110       52.78    185.16
  FVC LT                134   0.66      4.54      23.69    0.8
  FVC %                 134   19.3      121.7     65.6     194.25
  FEV~1~/FVC, %         134   24.44     5,064     959      43.25
  Heart rate            127   51        114       77.57    12.45
  QRS duration, ms      127   66        170       92.56    13.79

**Abbreviations:** CAT, COPD Assessment Test; CRP, C-reactive protein; FEV~1~, forced expiratory volume in 1 second; FVC, forced vital capacity; HB, hemoglobin; HCT, hematocrit; RBC, red blood cell; WBC, white blood cell.

###### 

Tp--Te values compared between patients with COPD and controls

  Tp--Te intervals   Control group   Case group     *p*-value                  
  ------------------ --------------- -------------- ----------- -------------- ---------------------------------------------------
  Tp--Te V1          64.9±20.6       61 (40--123)   82.2±19.5   79 (43--154)   0.00[a](#tfn5-copd-13-2157){ref-type="table-fn"}
  Tp--Te V2          81.9±16.4       84 (52--119)   90.3±18.4   86 (49--145)   0.017[a](#tfn5-copd-13-2157){ref-type="table-fn"}
  Tp--Te V3          79.3±15.6       78 (51--109)   90.6±15.8   90 (32--141)   0.00[a](#tfn5-copd-13-2157){ref-type="table-fn"}
  Tp--Te V4          70.3±12.4       71 (43--98)    89.7±16.9   89 (30--129)   0.00[a](#tfn5-copd-13-2157){ref-type="table-fn"}
  Tp--Te V5          75.3±11.7       75 (47--102)   86.9±17.7   85 (54--185)   0.00[a](#tfn5-copd-13-2157){ref-type="table-fn"}
  Tp--Te V6          68.6±12.3       69 (40--89)    84.6±15.9   85 (42--128)   0.00[a](#tfn5-copd-13-2157){ref-type="table-fn"}

**Note:**

Mann--Whitney *U*-test.

**Abbreviations:** SD, standard deviation; Tp--Te, interval between the peak and end of the T wave.

###### 

AUC values of Tp--Te compared between control and COPD groups

  Tp--Te intervals   AUC     95% CI         *p*-value
  ------------------ ------- -------------- -----------
  Tp--Te V1          0.765   0.657--0.873   \<0.001
  Tp--Te V2          0.631   0.535--0.727   0.013
  Tp--Te V3          0.708   0.611--0.805   \<0.001
  Tp--Te V4          0.831   0.765--0.896   \<0.001
  Tp--Te V5          0.716   0.629--0.803   \<0.001
  Tp--Te V6          0.786   0.712--0.860   \<0.001
  ROC curve                                 

**Abbreviations:** AUC, area under the curve; CI, confidence interval; ROC, receiver operating characteristic; Tp--Te, interval between the peak and end of the T wave.

###### 

Tp--Te V4 values compared between in COPD stages

  COPD stages                   Tp--Te V4   Tp--Te V4 \>80   *p*-value                                                  
  ----------------------------- ----------- ---------------- --------------------------------------------------- ------ --
  Combined assessment of COPD                                0.005[a](#tfn8-copd-13-2157){ref-type="table-fn"}          
   Stage A                      85.0±17.6   85.0             30                                                  65.2   
   Stage B                      86.0±16.7   84.5             16                                                  69.6   
   Stage C                      91.8±16.6   92.5             18                                                  69.2   
   Stage D                      96.6±14.0   96.5             36                                                  92.3   

**Note:**

Kruskal--Wallis (Mann--Whitney *U*-test).

**Abbreviations:** SD, standard deviation; Tp--Te, interval between the peak and end of the T wave.
